International Journal of Innovative Research and Scientific Studies, 8(2) 2025, pages: 3857-3871

ISSN: 2617-6548

URL: www.ijirss.com

Business analytics as a driver of organizational performance: Evidence from the pharmaceutical industry

Karim Soliman[1*], Afroze Nazneen[2], Adina Ambreen[3], Rasheedul Haque[4], Vikramjeet Jeet[5]

[1]*College of Business Administration, University of Business and Technology, Jeddah, Saudi Arabia.*
[1]*College of International Transport and Logistics, Arab Academy for Science, Technology, and Maritime Transport, Cairo, Egypt.*
[2]*Department of Business Administration, College of Business, University of Jeddah, Jeddah, Saudi Arabia.*
[3]*Student, Department of Commerce, Aligarh Muslim University, Aligarh, India.*
[4]*MAHSA University, Kuala Lumpur, Malaysia.*
[5]*Department of Business Administration, College of Business, University of Jeddah, Jeddah, Saudi Arabia.*

Corresponding author: Karim Soliman (*Email: k.soliman@ubt.edu.sa*)

Abstract

This study investigates the role of business analytics in enhancing organizational performance within the pharmaceutical industry. Business analytics, encompassing data collection, analytical tools, technology, human resources, strategic alignment, performance measurement, and compliance, is crucial for driving informed decision-making and strategic planning. A quantitative approach was employed, surveying 162 professionals across various managerial levels in pharmaceutical companies. A structured questionnaire assessed the impact of business analytics on organizational performance, focusing on financial, operational, market, employee, and sustainability metrics. Data were analyzed using SPSS software, with reliability, descriptive, and regression analyses conducted to evaluate the relationship between business analytics and performance outcomes. The results revealed a high Cronbach's Alpha value (0.980), indicating excellent reliability. Descriptive statistics showed moderate agreement with business analytics practices, while regression analysis demonstrated a strong positive correlation (R = 0.762) between business analytics and organizational performance, explaining 58% of the variance. The findings underscore the critical role of business analytics in improving financial performance, operational efficiency, market share, employee productivity, and sustainability within the pharmaceutical industry. Organizations are encouraged to invest in advanced analytics tools and technologies to drive strategic alignment and enhance overall performance.

Keywords: Business analytics, innovation, operational performance, market performance, organizational performance, supply chain performance, sustainability performance.

DOI: 10.53894/ijirss.v8i2.6114
Funding: This study received no specific financial support.
History: Received: 28 February 2025 / **Revised:** 1 April 2025 / **Accepted:** 3 April 2025 / **Published:** 11 April 2025

Competing Interests: The authors declare that they have no competing interests.
Authors' Contributions: All authors contributed equally to the conception and design of the study. All authors have read and agreed to the published version of the manuscript.

Transparency: The authors confirm that the manuscript is an honest, accurate, and transparent account of the study; that no vital features of the study have been omitted; and that any discrepancies from the study as planned have been explained. This study followed all ethical practices during writing.
Publisher: Innovative Research Publishing

1. Introduction

In today's rapidly evolving business landscape, the pharmaceutical industry stands at the forefront of integrating advanced technologies to drive innovation and improve organizational performance [1]. One such technological advancement that has garnered significant attention is business analytics, which encompasses a variety of techniques and tools designed to extract insights from data, facilitating informed decision-making and strategic planning [2]. This paper aims to explore the impact of using business analytics on organizational performance within the pharmaceutical industry, shedding light on the various dimensions through which analytics contributes to enhanced business outcomes.

1.1. Business Analytics

Business analytics involves the systematic computational analysis of data, which is pivotal in uncovering patterns, predicting trends, and aiding decision-making processes [3]. Business analytics leverages technology and infrastructure, human resources and skills, and strategic alignment and management to convert raw data into actionable insights [4]. Additionally, it encompasses performance measurement and compliance, and ethics to ensure that the insights derived are not only effective but also aligned with regulatory standards and organizational values [5].

1.2. Organizational Performance

Organizational performance, a multifaceted concept, refers to how well an organization achieves its objectives and goals [6]. In the context of the pharmaceutical industry, this encompasses financial performance, organizational performance, market performance, employee performance, and sustainability performance. Financial performance is often measured through metrics such as revenue growth, profit margins, and return on investment [7]. Organizational performance includes aspects like operational efficiency, product development, and innovation [8]. Market performance evaluates the organization's market share, customer satisfaction, and competitive positioning [9]. Employee performance looks at productivity, engagement, and retention rates, while sustainability performance focuses on the organization's environmental and social impact [10].

1.2.1. Business Analytics and Organizational Performance

Business analytics plays a pivotal role in enhancing organizational performance. Key components of business analytics include data collection and management, advanced analytical tools and techniques, robust technology infrastructure, human resources and skills, strategic alignment, and performance measurement frameworks [11].

Furthermore, analytical tools and techniques, such as predictive modelling and machine learning, enable organizations to identify trends, forecast outcomes, and optimize operations [12].

2. Review of Literature

The pharmaceutical industry operates within a complex and highly regulated environment, where the ability to harness and analyze data effectively can provide a significant competitive advantage [13]. This literature review explores the multifaceted impact of business analytics on organizational performance within the pharmaceutical industry. It examines the critical sub-variables of business analytics, including data collection and management, analytical tools and techniques, technology and infrastructure, human resources and skills, strategic alignment and management, performance measurement, and compliance and ethics. Additionally, it assesses the influence of business analytics on various aspects of organizational performance, such as financial, operational, market, employee, and sustainability performance, culminating in an analysis of the overall role of business analytics on organizational performance.

2.1. Business Analytics

2.1.1. Data Collection and Management

Effective data collection and management are the cornerstones of successful business analytics initiatives [2]. In the pharmaceutical industry, data is sourced from clinical trials, R&D, manufacturing processes, and market interactions, making integration and management challenging yet critical [14]. The complexity and volume of data necessitate sophisticated data management systems capable of handling big data and ensuring compliance with regulatory standards.

2.2. Analytical Tools and Techniques

The choice of analytical tools and techniques significantly influences the effectiveness of business analytics [15]. Predictive analytics, which forecasts future trends based on historical data, is particularly beneficial for anticipating market demand and optimizing supply chains in the pharmaceutical sector [16]. Prescriptive analytics provides specific recommendations, enhancing decision-making processes in areas such as drug pricing and marketing strategies.

2.3. Technology and Infrastructure

The technological infrastructure supporting business analytics includes hardware, software, and cloud computing capabilities [17]. The adoption of big data technologies and cloud computing has revolutionized data storage, processing, and

analysis [18]. For pharmaceutical companies, investing in advanced analytics platforms and tools is essential to process large datasets efficiently and derive real-time insights [19]. Cloud-based solutions offer scalability and flexibility, allowing organizations to manage and analyze data more effectively, which is crucial for maintaining a competitive edge in the industry [20].

2.4. Human Resources and Skills

The human element is vital for the successful implementation of business analytics. Skilled data scientists and analysts who can interpret complex data and generate actionable insights are indispensable [21]. In the pharmaceutical industry, the expertise of these professionals is critical for navigating the intricacies of clinical data, regulatory requirements, and market dynamics. Continuous training and development programs are necessary to keep the workforce updated with the latest analytical tools and techniques, fostering a culture of data-driven decision-making [22].

2.5. Strategic Alignment and Management

For business analytics to drive organizational performance, it must be aligned with the strategic objectives of the organization. Senior management support and commitment are crucial for integrating analytics into the decision-making processes [11]. In the pharmaceutical industry, aligning analytics with strategic areas such as drug development, marketing, and supply chain management ensures that data-driven insights contribute to achieving broader organizational goals [23]. A culture that values data-driven decision-making and continuous improvement is essential for maximizing the benefits of business analytics [24].

2.6. Performance Measurement

Measuring the impact of business analytics on organizational performance involves identifying and tracking key performance indicators (KPIs) such as return on investment (ROI), operational efficiency, and customer satisfaction [25]. In the pharmaceutical industry, performance measurement also includes evaluating the success of analytics in accelerating drug development timelines, reducing costs, and improving patient outcomes. Systematic performance measurement helps organizations identify areas for improvement and ensure that analytics initiatives deliver tangible benefits [26].

2.7. Compliance and Ethics

Compliance with regulatory requirements and ethical standards is a critical consideration for pharmaceutical companies using business analytics [27]. The handling of sensitive data, including patient information and proprietary research, necessitates strict adherence to data privacy and security regulations [28]. Ensuring compliance with regulations such as the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR) is essential for maintaining trust and avoiding legal repercussions. Ethical considerations also involve ensuring transparency in data usage and protecting stakeholder interests [29].

2.8. Organizational Performance

2.8.1. Financial Performance

The impact of business analytics on financial performance is a primary area of interest for pharmaceutical companies. Studies have shown that effective use of analytics can lead to cost savings, revenue growth, better decision making, and improved profit margins [30]. In the pharmaceutical industry, analytics can optimize pricing strategies, enhance sales forecasting, and identify new revenue streams.

2.8.2. Operational Performance

By optimizing manufacturing processes, improving supply chain management, and reducing waste, pharmaceutical companies can achieve greater operational effectiveness [31]. Real-time data analysis and predictive maintenance can prevent equipment failures and ensure continuous production [32]. Additionally, analytics can improve inventory management by accurately forecasting demand and reducing stockouts and overstock situations [33].

2.8.3. Market Performance

Business analytics enhances market performance by providing insights into customer behavior, market trends, and competitive dynamics [34]. In the pharmaceutical industry, analytics can inform targeted marketing campaigns, optimize sales strategies, and improve customer relationship management [35]. Predictive analytics helps organizations anticipate market changes and respond proactively, thereby improving market share and customer acquisition [36].

2.8.4. Employee Performance

The use of business analytics can positively influence employee performance by providing actionable insights that enhance productivity and satisfaction [37]. In the pharmaceutical industry, analytics can support workforce management, identify skill gaps, and enhance training programs [38]. Organizations that foster a data-driven culture and invest in employee development are more likely to experience higher levels of productivity and employee engagement [39]. Analytics can also improve talent acquisition and retention by identifying the most effective hiring and retention strategies [40].

2.8.5. Sustainability Performance

Sustainability performance is increasingly important for pharmaceutical companies as they seek to address environmental and social challenges [41]. Business analytics supports sustainability initiatives by providing insights into resource consumption, waste management, and environmental impact [42]. Analytics can help organizations monitor and reduce their carbon footprint, optimize energy usage, and improve sustainability reporting. In the pharmaceutical industry, analytics can also support social responsibility efforts by identifying opportunities for community engagement and ensuring ethical supply chain practices [43].

2.8.6. Role of Business Analytics on Organizational Performance

The role of business analytics in enhancing organizational performance is multifaceted and significant [44]. By transforming data into actionable insights, business analytics enables pharmaceutical companies to make informed decisions, optimize operations, and achieve strategic objectives [45].

Operational performance is enhanced through the optimization of manufacturing processes, supply chain management, and inventory control, resulting in increased efficiency and reduced costs [46]. Market performance benefits from targeted marketing campaigns, customer insights, and competitive analysis, leading to greater market share and customer acquisition [7].

Employee performance is positively impacted by data-driven workforce management, skills development, and talent retention strategies [47]. Sustainability performance is improved through the identification and implementation of environmentally and socially responsible practices, supported by robust analytics [48].

Overall, business analytics serves as a strategic enabler that aligns with organizational goals, enhances decision-making capabilities, and drives performance improvements across various dimensions [49]. The pharmaceutical industry, with its reliance on data and complex operational landscape, stands to gain significantly from the effective implementation of business analytics [50]. As organizations continue to invest in advanced analytics capabilities, the potential for achieving superior organizational performance becomes increasingly attainable [51].

The literature review highlights the critical role of business analytics in driving organizational performance within the pharmaceutical industry [51]. By exploring the various sub-variables of business analytics and their impact on financial, operational, market, employee, and sustainability performance, the review underscores the multifaceted benefits of analytics [52]. The integration of advanced analytical tools and techniques, supported by robust data management, technological infrastructure, and skilled human resources, enables pharmaceutical companies to optimize their operations and achieve strategic objectives [53].

2.8.7. Research Gap

Despite the recognized potential of business analytics to enhance organizational performance in the pharmaceutical industry, there remains a significant gap in empirical studies that comprehensively examine this relationship [54]. Current literature often focuses on isolated aspects of business analytics, such as data management or predictive modelling, without integrating these elements to provide a holistic view of their impact on various performance metrics [55]. Additionally, most studies are concentrated on financial and operational performance, leaving areas like employee performance, sustainability, and compliance underexplored. Furthermore, the unique challenges and opportunities within the pharmaceutical sector, such as stringent regulatory environments and complex supply chains, necessitate targeted research that addresses industry-specific nuances. This study aims to fill these gaps by providing a comprehensive analysis of how business analytics influences multiple dimensions of organizational performance in the pharmaceutical industry [56], thereby offering actionable insights for industry practitioners and contributing to the academic discourse.

3. Research Methodology

3.1. Research Objective:

- To identify the impact of using business analytics on organizational performance within the pharmaceutical industry.

3.2. Measures

Table 1.
Table showing Variables for the study.

Business Analytics	Data Collection and Management	BA1	Our organization has a robust system for collecting high-quality data.
		BA2	Data integration processes in our organization are efficient and reliable.
		BA3	Data governance policies are strictly followed within our organization.
		BA4	The data we collect is regularly updated and accurate.
		BA5	We have effective mechanisms in place to manage and store our data securely.
	Analytical Tools and Techniques	BA6	Our organization utilizes advanced predictive analytics tools.
		BA7	Descriptive analytics is effectively used to understand past performance.
		BA8	We employ prescriptive analytics to guide our decision-making processes.
		BA9	Machine learning techniques are integrated into our business analytics strategy.
		BA10	Statistical analysis is a core component of our data analysis practices.
		BA11	Our analytical tools are user-friendly and accessible to relevant staff.
	Technology and Infrastructure	BA12	Our IT infrastructure supports our business analytics needs.
		BA13	We use cutting-edge software solutions for data analysis.
		BA14	Cloud computing is an integral part of our data storage strategy.
		BA15	Our organization leverages big data technologies to gain insights.
		BA16	Technology upgrades are made regularly to support business analytics.
	Human Resources and Skills	BA17	Our employees have strong analytical skills.
		BA18	We provide regular training and development programs in business analytics.
		BA19	Decision-making skills are emphasized in our organization's training programs.
		BA20	There is a high level of collaboration between departments for data analysis.
		BA21	Our team is proficient in using business analytics tools.
	Strategic Alignment and Management	BA22	Business analytics is well-integrated into our overall business strategy.
		BA23	Senior management actively supports the use of business analytics.
		BA24	Our organizational culture promotes data-driven decision-making.
		BA25	We align our analytics initiatives with strategic business goals.
		BA26	Business analytics projects receive adequate resources and attention.
	Performance Measurement	BA27	We have clearly defined key performance indicators (KPIs) for measuring success.
		BA28	Business analytics helps us achieve a high return on investment (ROI).
		BA29	Our operational efficiency has improved due to business analytics.
		BA30	Customer satisfaction metrics are effectively tracked using analytics.
		BA31	Performance metrics are regularly reviewed and updated based on analytical insights.
	Compliance and Ethics	BA32	Our organization strictly adheres to regulatory compliance in data handling.
		BA33	We have strong policies in place to ensure data privacy.
		BA34	The ethical use of data is a priority in our analytics processes.
		BA35	We regularly conduct audits to ensure compliance with data regulations.
		BA36	Our employees are well-trained in ethical standards related to business analytics.
Organizational Performance	Financial Performance	OP1	Our organization consistently achieves its revenue growth targets.
		OP2	We maintain high profit margins across our products and services.
		OP3	The return on investment (ROI) from our projects is satisfactory.
		OP4	Cost reduction initiatives have been effectively implemented in our organization.
		OP5	Financial performance metrics are regularly reviewed and analyzed for improvement.
		OP6	Our financial performance is stronger than that of our key competitors.
		OP7	We have effective strategies in place to manage and reduce operational costs.

	Operational Performance	OP8	Our production processes are highly efficient and effective.
		OP9	We have optimized our operations to minimize waste and maximize output.
		OP10	Our supply chain management processes are seamless and efficient.
		OP11	Inventory management practices in our organization are highly effective.
		OP12	We regularly review and improve our operational processes.
		OP13	Our organization quickly adapts to changes in operational demands.
		OP14	Operational performance metrics are a key focus of our management team.
	Market Performance	OP15	Our market share has been steadily increasing over the past few years.
		OP16	We consistently achieve our sales growth targets.
		OP17	Customer acquisition strategies in our organization are highly effective.
		OP18	Our marketing efforts have significantly improved our market presence.
		OP19	We are perceived as a market leader in our industry.
		OP20	We respond quickly to market changes and customer needs.
		OP21	Our product/service offerings are well-received by our target market.
	Employee Performance	OP22	Our employees are highly productive and efficient in their roles.
		OP23	Employee satisfaction levels are high within our organization.
		OP24	We have low employee turnover rates.
		OP25	Our organization is successful in attracting top talent in the industry.
		OP26	Employees receive adequate training and development opportunities.
		OP27	There is a strong sense of teamwork and collaboration among employees.
		OP28	Employee performance is regularly monitored and reviewed for improvement.
	Sustainability Performance	OP29	Our organization is committed to reducing its environmental impact.
		OP30	We have effective programs in place to promote social responsibility.
		OP31	Corporate governance practices in our organization are transparent and ethical.
		OP32	We have made significant progress in our sustainability goals.
		OP33	Sustainability initiatives are a key part of our business strategy.
		OP34	We actively engage with stakeholders on sustainability issues.
		OP35	Our sustainability performance is regularly reported and reviewed.

The research methodology for this study involves a quantitative approach to analyze the impact of business analytics on organizational performance in the pharmaceutical industry. A structured survey was administered to 162 respondents, who are professionals working in various pharmaceutical companies at different managerial levels. The survey includes questions designed to measure the use of business analytics tools and techniques, and their perceived impact on organizational performance across different dimensions such as financial performance, operational efficiency, and market share, etc.

The data collected from the survey is analyzed using SPSS software. Initially, a reliability analysis is conducted to ensure the consistency and dependability of the survey instruments. This is followed by descriptive statistics to summarize the key characteristics of the data, providing an overview of how business analytics is currently utilized in the industry. To address the study's objective, regression analysis is performed to examine the relationship between the use of business analytics and various organizational performance metrics. The regression model quantifies the impact of business analytics on performance indicators, enabling a deeper understanding of the effectiveness of analytics practices in the pharmaceutical sector.

This methodology ensures a robust analysis of the data, providing valuable insights into the role of business analytics in enhancing organizational performance in the pharmaceutical industry.

3.3. Proposed Framework



Figure 1.
Conceptual Model.

4. Data Analysis and Interpretation

In order to achieve the aforementioned objective, firstly, reliability analysis is applied, followed by descriptive analysis, and then regression analysis.

4.1. Reliability Analysis

Table 2.
Reliability Statistics.

Cronbach's Alpha	N of Items
0.980	71

The Cronbach's Alpha value of .980 indicates an excellent level of internal consistency and reliability for the 71-item scale. This high alpha suggests that the items are highly correlated and measure the same underlying construct effectively, making the scale very reliable for assessing business analytics and organizational performance.

4.2. Descriptive Analysis

Descriptive statistics are applied to identify the impact of business analytics on organizational performance by summarizing and highlighting key patterns and trends within the data. By calculating means and standard deviations, researchers can understand the level of agreement or disagreement with each item, revealing areas of strength and weakness in business analytics practices. This information helps identify which aspects of business analytics are most effective in enhancing organizational performance, particularly within the pharmaceutical industry.

Table 3.
Descriptive Statistics.

	N	Minimum	Maximum	Mean	Std. Deviation
BA1	162	1	5	3.25	1.246
BA2	162	1	5	3.19	1.252
BA3	162	1	5	3.27	1.333
BA4	162	1	5	3.27	1.230
BA5	162	1	5	3.34	1.247
BA6	162	1	5	3.35	1.248
BA7	162	1	5	3.10	1.375
BA8	162	1	5	3.27	1.295
BA9	162	1	5	3.43	1.245
BA10	162	1	5	3.28	1.291
BA11	162	1	5	3.28	1.237
BA12	162	1	5	3.28	1.268
BA13	162	1	5	3.28	1.213
BA14	162	1	5	3.28	1.186
BA15	162	1	5	3.23	1.282
BA16	162	1	5	3.38	1.291
BA17	162	1	5	3.36	1.254
BA18	162	1	5	3.29	1.284
BA19	162	1	5	3.23	1.244
BA20	162	1	5	3.29	1.274
BA21	162	1	5	3.27	1.270
BA22	162	1	5	3.26	1.278
BA23	162	1	5	3.35	1.267
BA24	162	1	5	3.07	1.379
BA25	162	1	5	3.06	1.289
BA26	162	1	5	3.08	1.290
BA27	162	1	5	3.12	1.225
BA28	162	1	5	3.15	1.202
BA29	162	1	5	3.14	1.275
BA30	162	1	5	3.18	1.318
BA31	162	1	5	3.19	1.338
BA32	162	1	5	3.15	1.326
BA33	162	1	5	3.14	1.265
BA34	162	1	5	3.09	1.265
BA35	162	1	5	3.13	1.291
BA36	162	1	5	3.10	1.352

OP1	162	1	5	3.22	1.295
OP2	162	1	5	3.08	1.337
OP3	162	1	5	3.04	1.253
OP4	162	1	5	2.91	1.332
OP5	162	1	5	3.08	1.280
OP6	162	1	5	2.98	1.374
OP7	162	1	5	2.96	1.292
OP8	162	1	5	3.05	1.332
OP9	162	1	5	3.07	1.281
OP10	162	1	5	2.95	1.250
OP11	162	1	5	2.98	1.330
OP12	162	1	5	3.03	1.302
OP13	162	1	5	3.04	1.297
OP14	162	1	5	2.94	1.235
OP15	162	1	5	2.99	1.314
OP16	162	1	5	2.90	1.298
OP17	162	1	5	2.90	1.175
OP18	162	1	5	2.96	1.285
OP19	162	1	5	3.02	1.330
OP20	162	1	5	3.01	1.273
OP21	162	1	5	3.01	1.295
OP22	162	1	5	3.07	1.264
OP23	162	1	5	3.07	1.247
OP24	162	1	5	3.07	1.283
OP25	162	1	5	3.15	1.307
OP26	162	1	5	2.98	1.285
OP27	162	1	5	3.08	1.216
OP28	162	1	5	3.08	1.314
OP29	162	1	5	3.07	1.288
OP30	162	1	5	3.13	1.366
OP31	162	1	5	3.05	1.323
OP32	162	1	5	3.05	1.260
OP33	162	1	5	3.28	1.320
OP34	162	1	5	3.23	1.292
OP35	162	1	5	3.27	1.276
Valid N (listwise)	162				

The descriptive statistics table provides insights into the responses for each item in the survey. Each item was rated on a scale of 1 to 5, with a sample size of 162. The mean scores for the items range from 2.90 to 3.43, indicating that, on average, respondents rated the items slightly above the midpoint of the scale, suggesting a moderate level of agreement with the statements.

The standard deviations range from 1.175 to 1.379, showing a relatively high variance in responses, which indicates a diverse set of opinions among the respondents. Items like BA9 (mean = 3.43) and BA16 (mean = 3.38) received relatively higher average scores, suggesting that respondents generally agree with the statements regarding predictive analytics tools and technology upgrades. In contrast, items like OP16 (mean = 2.90) and OP17 (mean = 2.90) received lower scores, indicating potential areas for improvement in market performance and customer acquisition strategies. Overall, the data reflects a diverse and varied perception of business analytics and organizational performance across different aspects.

4.3. Regression Analysis

Regression analysis is applied to determine the impact of business analytics on organizational performance by quantifying the relationship between the two variables. It helps in identifying the extent to which changes in business analytics practices can predict improvements in performance outcomes. By analyzing this relationship, regression provides insights into which specific analytics practices significantly influence performance, enabling targeted improvements and strategic decisions within the pharmaceutical industry.

Table 4.
Descriptive Statistics.

	Mean	**Std. Deviation**	**N**
Organizational Performance	3.0485	.85760	162
Business Analytics	3.1324	.89115	162

The descriptive statistics for organizational performance and business analytics indicate moderate agreement among respondents, with mean scores of 3.05 and 3.13, respectively, on a 5-point scale. The standard deviations of 0.86 and 0.89 suggest some variability in responses. This implies that while there is a positive perception of both organizational performance and business analytics, there is still room for improvement. The data can help identify specific areas for enhancing performance in the pharmaceutical industry.

Table 5.
Correlations

		Organizational Performance	Business Analytics
Pearson Correlation	Organizational Performance	1.000	0.762
	Business Analytics	0.762	1.000
Sig. (1-tailed)	Organizational Performance	.	0.000
	Business Analytics	0.000	.
N	Organizational Performance	162	162
	Business Analytics	162	162

The correlation analysis reveals a strong positive relationship between business analytics and organizational performance, with a Pearson correlation coefficient of 0.762. This indicates that as business analytics practices improve, organizational performance is likely to enhance significantly as well. The p-value (Sig. = .000) suggests that this correlation is statistically significant, meaning the observed relationship is unlikely to be due to chance. This supports the hypothesis that effective use of business analytics positively impacts organizational performance in the pharmaceutical industry.

Table 6.
Model Summary[b].

Model	R	R Square	Adjusted R Square	Std. Error of the Estimate
1	0.762[a]	0.580	0.578	0.55726

Note: a. Predictors: (Constant), Business_Analytics.
b. Dependent Variable: Organizational Performance.

The model summary provides insights into the relationship between business analytics and organizational performance. The correlation coefficient (R) is 0.762, indicating a strong positive linear relationship between the two variables. The R Square value of 0.580 suggests that approximately 58% of the variance in organizational performance can be explained by business analytics practices. This is a substantial portion, highlighting the significant impact of business analytics on performance outcomes. The Adjusted R Square of 0.578 accounts for the number of predictors in the model and indicates that the model is a good fit for the data. The standard error of the estimate is 0.55726, reflecting the average distance that the observed values fall from the regression line. This relatively low standard error suggests that the model's predictions are fairly accurate.

Overall, these statistics indicate that business analytics is a key predictor of organizational performance in the pharmaceutical industry. The strong positive relationship underscores the importance of investing in and improving analytics practices to achieve better performance outcomes.

Table 7.
ANOVA[a].

Model		Sum of Squares	df	Mean Square	F	Sig.
1	Regression	68.727	1	68.727	221.313	0.000[b]
	Residual	49.687	160	0.311		
	Total	118.413	161			

Note : a. Dependent Variable: Organizational_Performance.
b. Predictors: (Constant), Business_Analytics.

The ANOVA table indicates that the regression model predicting organizational performance from business analytics is statistically significant. The F-value of 221.313 and the p-value of .000 demonstrate that the model explains a significant portion of the variance in organizational performance beyond what would be expected by chance. The sum of squares for the regression (68.727) compared to the residual (49.687) suggests that business analytics has a substantial impact on performance, making it a crucial factor for improving organizational outcomes in the pharmaceutical industry.

Table 8.
Coefficients[a].

Model		Unstandardized Coefficients		Standardized Coefficients	t	Sig.
		B	Std. Error	Beta		
1	(Constant)	0.752	0.160		4.686	0.000
	Business_Analytics	0.733	0.049	0.762	14.877	0.000
a. Dependent Variable: Organizational_Performance						

The regression equation for predicting Organizational Performance is:

Organizational_Performance = 0.752 + 0.733 × Business_Analytics

Here, 0.752 is the intercept, and 0.733 is the coefficient for Business Analytics, showing its impact on Organizational Performance.

4.4. Plots for The Study



Figure 2.
Plots and Graphs of the Study.

The histogram shows the distribution of residuals, indicating how well the model fits the data. The histogram's shape approximates a normal distribution, suggesting that the residuals are normally distributed. This is essential for the validity of regression analysis. The mean residual value is close to zero, indicating that the model does not systematically overestimate or underestimate the actual values, thus providing unbiased predictions. The P-P plot compares observed cumulative probabilities of residuals to expected probabilities under a normal distribution. The data points closely follow the 45-degree line, indicating that the residuals are normally distributed. This supports the assumption of normality, which is crucial for the reliability of regression results, confirming that the model's predictions are valid. This scatterplot depicts the relationship between standardized residuals and predicted values [57]. A random scatter of points with no discernible pattern is observed, indicating homoscedasticity, or constant variance of residuals. The absence of patterns suggests that the model is appropriate, as the residuals do not show any systematic variation with predicted values, affirming the model's suitability for the data.

The charts collectively suggest that the regression model assessing the impact of business analytics on organizational performance in the pharmaceutical industry meets the key assumptions of linear regression: normality and homoscedasticity of residuals. These findings indicate that the regression results are reliable, supporting the conclusion that business analytics significantly influences organizational performance within the pharmaceutical sector.

5. Results and Conclusion

The Cronbach's Alpha value of 0.980 indicates an excellent level of internal consistency and reliability for the 71-item scale. This high alpha suggests that the items are highly correlated and measure the same underlying construct effectively. This reliability is crucial for assessing business analytics and organizational performance, ensuring that the scale provides consistent and dependable results across different respondents.

Descriptive statistics were applied to identify the impact of business analytics on organizational performance by summarizing key patterns and trends within the data [58]. The analysis included calculating means and standard deviations to understand the level of agreement or disagreement with each item [59]. The mean scores for the items ranged from 2.90 to 3.43, indicating that respondents generally rated the items slightly above the midpoint of the scale. This suggests a moderate level of agreement with the statements, reflecting a positive perception of business analytics practices. The standard deviations, ranging from 1.175 to 1.379, indicate a relatively high variance in responses, highlighting a diverse set of opinions among the respondents. Items like BA9 (mean = 3.43) and BA16 (mean = 3.38) received higher average scores, suggesting agreement with statements regarding predictive analytics tools and technology upgrades. Conversely, items like OP16 (mean = 2.90) and OP17 (mean = 2.90) received lower scores, indicating potential areas for improvement in market performance and customer acquisition strategies.

Regression analysis quantified the relationship between business analytics and organizational performance. The model summary shows a strong positive correlation (R = 0.762) between the variables, with an R Square value of 0.580, indicating that approximately 58% of the variance in organizational performance can be explained by business analytics practices. The Adjusted R Square of 0.578 suggests that the model is a good fit for the data. The regression equation, Organizational_Performance = 0.752 + 0.733 × Business_Analytics, shows that business analytics significantly impacts organizational performance. The ANOVA table confirms the model's statistical significance (F-value = 221.313, p-value = 0.000), highlighting that business analytics is a crucial factor for improving performance in the pharmaceutical industry.

The histogram of residuals approximates a normal distribution, essential for the validity of the regression analysis. The P-P plot shows that residuals closely follow the 45-degree line, supporting the assumption of normality. The scatterplot of standardized residuals versus predicted values indicates homoscedasticity, with no discernible pattern in the residuals. These plots confirm that the regression model meets the assumptions of linear regression, suggesting that the findings are reliable and that business analytics significantly influences organizational performance in the pharmaceutical sector.

The combined analysis of reliability, descriptive statistics, and regression underscores the significant impact of business analytics on organizational performance within the pharmaceutical industry [60]. The high Cronbach's Alpha value attests to the reliability of the measures used. Descriptive statistics reveal a generally positive perception of business analytics practices, although some areas need improvement. Regression analysis highlights a strong positive relationship between business analytics and organizational performance, explaining a substantial portion of the variance. These findings collectively suggest that investing in and improving business analytics practices can lead to better performance outcomes, emphasizing its critical role in the pharmaceutical industry.

5.1. Implications of the Study

The findings of the study carry significant social and managerial implications. From a social perspective, the integration of business analytics in the pharmaceutical industry can lead to substantial advancements in public health outcomes. By leveraging advanced data analytics, pharmaceutical companies can expedite the drug development process, ensuring that new, effective medications reach the market more swiftly [61]. This can be particularly critical in responding to public health emergencies, such as pandemics, where timely access to treatments and vaccines is crucial [62]. Enhanced data analysis also enables better monitoring of drug efficacy and safety post-market, contributing to higher standards of patient care and safety [63].

Moreover, business analytics facilitates personalized medicine by allowing companies to analyze genetic, environmental, and lifestyle data to tailor treatments to individual patients [64]. This shift from a one-size-fits-all approach to personalized healthcare can significantly improve treatment efficacy and reduce healthcare costs by targeting interventions more precisely [65]. This advancement in personalized medicine not only improves patient health but also addresses issues of accessibility and equity in healthcare, as treatments can be tailored to diverse populations with varying needs and conditions [66].

From a managerial perspective, the adoption of business analytics within the pharmaceutical industry leads to more informed decision-making and strategic planning [67]. Managers equipped with insights derived from data analytics can make better decisions regarding resource allocation, R&D investments, and market strategies [68]. For instance, predictive analytics can provide forecasts on market demand, enabling companies to optimize their supply chains, reduce waste, and manage inventory more effectively [69]. This leads to cost savings and improved operational efficiency, enhancing the overall competitiveness of the organization [70].

Furthermore, business analytics supports risk management by identifying potential threats and opportunities through sophisticated data models [71]. In an industry as heavily regulated as pharmaceuticals, the ability to anticipate regulatory changes and compliance risks is invaluable [72]. Analytics can help in monitoring compliance with various regulations, thereby reducing the risk of costly legal issues and enhancing the company’s reputation among stakeholders [73]. This proactive approach to risk management also fosters a culture of continuous improvement and innovation, as organizations are better equipped to navigate the complexities of the regulatory landscape.

The implementation of business analytics also has significant implications for human resource management within the pharmaceutical industry. By analyzing workforce data, companies can identify skill gaps, optimize talent acquisition strategies, and design targeted training programs [74]. This not only enhances employee performance but also improves job satisfaction and retention rates [75]. A data-driven approach to HR management ensures that the organization has the right talent in place to drive innovation and achieve strategic goals. Additionally, performance analytics can help in setting clear, measurable objectives for employees, aligning their efforts with the company’s overall strategy, and fostering a more engaged and productive workforce [76].

Another critical managerial implication is the role of business analytics in driving strategic alignment and management. The ability to align analytics initiatives with the company’s strategic objectives ensures that data-driven insights contribute directly to achieving broader organizational goals [77]. Senior management support and commitment are crucial for integrating analytics into the decision-making processes. This strategic alignment ensures that the organization leverages data analytics not just as a tool for operational efficiency but as a strategic asset that drives long-term growth and sustainability [78].

In terms of market performance, business analytics provides pharmaceutical companies with deeper insights into customer behavior, market trends, and competitive dynamics. This enables more effective marketing campaigns, optimized sales strategies, and improved customer relationship management. For instance, segmenting customers based on their preferences and behaviors allows for more targeted and effective marketing efforts, leading to increased market share and customer loyalty [79]. Additionally, understanding market trends and competitive actions helps companies to adapt quickly to changes in the market environment, maintaining their competitive edge.

Business analytics also plays a pivotal role in enhancing sustainability performance. By providing insights into resource consumption, waste management, and environmental impact, analytics helps companies implement more sustainable practices [77]. This not only reduces the environmental footprint of the organization but also meets the growing demand from consumers and regulators for more sustainable business practices [80]. In the pharmaceutical industry, where the environmental impact of production processes can be significant, adopting sustainable practices supported by data analytics can lead to substantial improvements in sustainability performance [81].

Overall, the integration of business analytics into the pharmaceutical industry has far-reaching social and managerial implications. Socially, it contributes to improved public health outcomes, personalized medicine, and patient safety. Managerially, it enhances decision-making, risk management, human resource management, strategic alignment, market performance, and sustainability.

5.2. Future Scope of the Study

As the pharmaceutical industry continues to evolve, the integration of more advanced analytics, including artificial intelligence and machine learning, presents new avenues for enhancing organizational performance. Future research could delve deeper into the application of these technologies in predicting drug efficacy, optimizing clinical trials, and personalizing patient care. Additionally, the role of real-time data analytics in improving supply chain resilience and responding to global health crises warrants further exploration. Cross-industry comparisons could provide insights into best practices and innovative applications of business analytics in the pharmaceutical sector. Finally, longitudinal studies examining the long-term impact of business analytics on sustainability performance and regulatory compliance could offer valuable insights into how these practices evolve and mature over time.

References

[1] C. Okolo, J. Arowoogun, R. Chidi, and A. Adeniyi, "Telemedicine's role in transforming healthcare delivery in the pharmaceutical industry: A systematic review," *World Journal of Advanced Research and Reviews*, vol. 21, no. 2, pp. 1836-1856, 2024. https://doi.org/10.30574/wjarr.2024.21.2.0609

[2] A. Tuboalabo, J. Buinwi, U. Buinwi, C. Okatta, and E. Johnson, "Leveraging business analytics for competitive advantage: Predictive models and data-driven decision making," *International Journal of Management & Entrepreneurship Research*, vol. 6, no. 6, pp. 1997-2014, 2024. https://doi.org/10.51594/ijmer.v6i6.1239

[3] A. O. Adewusi, U. I. Okoli, E. Adaga, T. Olorunsogo, O. F. Asuzu, and D. O. Daraojimba, "Business intelligence in the era of big data: A review of analytical tools and competitive advantage," *Computer Science & IT Research Journal*, vol. 5, no. 2, pp. 415-431, 2024. https://doi.org/10.51594/csitrj.v5i2.791

[4] R. Khan, M. Usman, and M. Moinuddin, "From raw data to actionable insights: navigating the world of data analytics," *International Journal of Advanced Engineering Technologies and Innovations*, vol. 1, no. 4, pp. 142-166, 2024. https://doi.org/10.30574/ijaeti.2024.1.4.267

[5] N. R. Palakurti, "Governance strategies for ensuring consistency and compliance in business rules management," *Transactions on Latest Trends in Artificial Intelligence*, vol. 4, no. 4, pp. 1-20, 2023.

[6] U. E. Samuel, A. I. Prince, V. Ndubuaku, B. E. Udoh, and J. I. Okoh, "Effect of FinTech on cash holding: Quarterly evidence from Nigeria," *The Economics and Finance Letters*, vol. 10, no. 2, pp. 172–183, 2023. https://doi.org/10.18488/29.v10i2.3407

[7] N. N. Vibhakar, K. K. Tripathi, S. Johari, and K. N. Jha, "Identification of significant financial performance indicators for the Indian construction companies," *International Journal of Construction Management*, vol. 23, no. 1, pp. 13-23, 2023.

[8] S. Handoyo, H. Suharman, E. K. Ghani, and S. Soedarsono, "A business strategy, operational efficiency, ownership structure, and manufacturing performance: The moderating role of market uncertainty and competition intensity and its implication on open innovation," *Journal of Open Innovation: Technology, Market, and Complexity*, vol. 9, no. 2, p. 100039, 2023. https://doi.org/10.1016/j.joitmc.2023.100039

[9] M. Kharub and R. Sharma, "An integrated structural model of QMPs, QMS and firm's performance for competitive positioning in MSMEs," *Total Quality Management & Business Excellence*, vol. 31, no. 3-4, pp. 312-341, 2020. https://doi.org/10.1080/14783363.2018.1427500

[10] F. Amjad *et al.*, "Effect of green human resource management practices on organizational sustainability: the mediating role of environmental and employee performance," *Environmental Science and Pollution Research*, vol. 28, pp. 28191-28206, 2021. https://doi.org/10.1007/s11356-020-11307-9

[11] S. V. Shet, T. Poddar, F. W. Samuel, and Y. K. Dwivedi, "Examining the determinants of successful adoption of data analytics in human resource management–A framework for implications," *Journal of Business Research*, vol. 131, pp. 311-326, 2021. https://doi.org/10.1016/j.jbusres.2021.03.054

[12] J. P. Bharadiya and J. Bharadiya, "Machine learning and AI in business intelligence: Trends and opportunities," *International Journal of Computer*, vol. 48, no. 1, pp. 123-134, 2023.

[13] L. Fei *et al.*, "Factors affecting talent retention to ensure sustainable growth in the automation industry in Penang free industrial zone," *Kurdish Studies*, vol. 12, no. 1, pp. 3122-3143, 2024. https://doi.org/10.58262/ks.v12i1.226

[14] M. Sarkis, A. Bernardi, N. Shah, and M. M. Papathanasiou, "Emerging challenges and opportunities in pharmaceutical manufacturing and distribution," *Processes*, vol. 9, no. 3, p. 457, 2021. https://doi.org/10.3390/pr9030457

[15] Y. Duan, G. Cao, and J. S. Edwards, "Understanding the impact of business analytics on innovation," *European Journal of Operational Research*, vol. 281, no. 3, pp. 673-686, 2020. https://doi.org/10.1016/j.ejor.2018.06.021

[16] A. Nguyen, S. Lamouri, R. Pellerin, S. Tamayo, and B. Lekens, "Data analytics in pharmaceutical supply chains: State of the art, opportunities, and challenges," *International Journal of Production Research*, vol. 60, no. 22, pp. 6888-6907, 2022. https://doi.org/10.1080/00207543.2021.1950937

[17] A. Isa *et al.*, "Empirical evidence of sustainable development goals (SDGs) on talent management practices and employee engagement in government linked companies," *Journal of Lifestyle and SDGs Review*, vol. 5, no. 2, pp. e02672-e02672, 2025. https://doi.org/10.47172/2965-730X.SDGsReview.v5.n02.pe02672

[18] G. Aceto, V. Persico, and A. Pescapé, "Industry 4.0 and health: Internet of things, big data, and cloud computing for healthcare 4.0," *Journal of Industrial Information Integration*, vol. 18, p. 100129, 2020. https://doi.org/10.1016/j.jii.2020.100129

[19] Y. H. Chin, A. Rahman, R. Haque, A. Pang, and G. Connie, "Customer satisfaction in tourism service quality," *Scientific American*, vol. 4, pp. 3398-3402, 2019.

[20] C. Amajuoyi, L. Nwobodo, and M. Adegbola, "Transforming business scalability and operational flexibility with advanced cloud computing technologies," *Computer Science & IT Research Journal*, vol. 5, no. 6, pp. 1469-1487, 2024. https://doi.org/10.51594/csitrj.v5i6.1248

[21] S. Vinay, "Data scientist competencies and skill assessment: A comprehensive framework," *Journal ID*, vol. 1, no. 1, pp. 1-11, 2024.
[22] D. Prakash, "Data-driven management: The impact of big data analytics on organizational performance," *International Journal for Global Academic & Scientific Research*, vol. 3, no. 2, pp. 12-23, 2024. https://doi.org/10.55938/ijgasr.v3i2.74
[23] M. I. Khalil, R. Haque, A. R. bin S Senathirajah, B. Chowdhury, and S. Ahmed, "Modeling factors affecting SME performance in Malaysia," *International Journal of Operations and Quantitative Management*, vol. 28, no. 2, pp. 506-524, 2022. https://doi.org/10.46970/2022.28.2.6
[24] R. Chaudhuri, S. Chatterjee, D. Vrontis, and A. Thrassou, "Adoption of robust business analytics for product innovation and organizational performance: the mediating role of organizational data-driven culture," *Annals of Operations Research*, vol. 339, no. 3, pp. 1757-1791, 2024. https://doi.org/10.1007/s10479-021-04407-3
[25] P. Verma, V. Kumar, A. Mittal, B. Rathore, A. Jha, and M. S. Rahman, "The role of 3S in big data quality: a perspective on operational performance indicators using an integrated approach," *The TQM Journal*, vol. 35, no. 1, pp. 153-182, 2023. https://doi.org/10.1108/TQM-02-2021-0062
[26] R. A. Sheikh, S. Bhatia, S. G. Metre, and A. Y. A. Faqihi, "Strategic value realization framework from learning analytics: A practical approach," *Journal of Applied Research in Higher Education*, vol. 14, no. 2, pp. 693-713, 2022. https://doi.org/10.1108/JARHE-10-2020-0379
[27] Y. Hailong, A. Senathirajah, G. Connie, and R. Haque, "Key E-Dimensions influencing hotel website quality," *Res Militaris, European Journal of Military Studies*, vol. 12, no. 2, pp. 1567-1583, 2022.
[28] C. Thapa and S. Camtepe, "Precision health data: Requirements, challenges and existing techniques for data security and privacy," *Computers in Biology and Medicine*, vol. 129, p. 104130, 2021. https://doi.org/10.1016/j.compbiomed.2020.104130
[29] D. Tzimas and S. Demetriadis, "Ethical issues in learning analytics: A review of the field," *Educational Technology Research and Development*, vol. 69, pp. 1101-1133, 2021. https://doi.org/10.1007/s11423-021-09977-4
[30] C. S. Lee, P. Y. S. Cheang, and M. Moslehpour, "Predictive analytics in business analytics: decision tree," *Advances in Decision Sciences*, vol. 26, no. 1, pp. 1-29, 2022. https://doi.org/10.47654/v26y2022i1p1-30
[31] A. Z. Abideen and F. B. Mohamad, "Supply chain lead time reduction in a pharmaceutical production warehouse–a case study," *International Journal of Pharmaceutical and Healthcare Marketing*, vol. 14, no. 1, pp. 61-88, 2020. https://doi.org/10.1108/IJPHM-02-2019-0005
[32] S. Narayanan *et al.*, "Workplace romance and organisational performance: A case study of Malaysian organizations," *International Journal of Instructional Cases*, vol. 8, no. 1, pp. 121-134, 2024.
[33] R. Wolniak and W. Grebski, "Business analytics in the case of inventory management in Industry 4.0 conditions," *Zeszyty Naukowe Politechniki Śląskiej. Organizacja i Zarządzanie,* vol. 182, pp. 597-612, 2023.
[34] S. Ahmed, N. Abd Aziz, R. Haque, A. R. Bin S. Senathirajah, and S. Z. Qazi, "Digital transformation in Malaysian manufacturing: a study of change sensing and seizing capabilities," *Cogent Business & Management*, vol. 11, no. 1, p. 2392046, 2024. https://doi.org/10.1080/23311975.2024.2392046
[35] M. Shahbaz, C. Gao, L. Zhai, F. Shahzad, A. Luqman, and R. Zahid, "Impact of big data analytics on sales performance in pharmaceutical organizations: The role of customer relationship management capabilities," *Plos one*, vol. 16, no. 4, p. e0250229, 2021. https://doi.org/10.1371/journal.pone.0250229
[36] C. Ifedi, R. Haque, A. R. S. Senathirajah, and S. Z. Qazi, "Service quality influence on consumer satisfaction in the banking sector aimed at sustainable growth," *Revista de Gestão Social e Ambiental*, vol. 18, no. 7, pp. 1-30, 2024. https://doi.org/10.24857/rgsa.v18n7-032
[37] A. Luz and G. Olaoye, "Leveraging data for actionable insights and engagement strategies," EasyChair (No. 13218), 2024.
[38] N. Wickneswary *et al.*, "Factors influencing college students' educational enrolment choice in private higher education institution in Klang Valley, Malaysia," *Kurdish Studies*, vol. 12, no. 2, pp. 3674-3693, 2024. https://doi.org/10.58262/ks.v12i2.274
[39] C. Ramalingam, R. Haque, K. Jumbulingam, N. Salehhudin, L. Manickam, and S. Devasia, "Gender impeded: The lived experiences of transgenders at the workplace," *International Journal of Religion*, vol. 5, no. 4, pp. 150-162, 2024. https://doi.org/10.61707/afg0gr17
[40] J. Kaur, G. Madaan, S. Qazi, and P. Bhalla, "An explorative factor analysis of competency mapping for IT professionals," *Administrative Sciences*, vol. 13, no. 4, p. 98, 2023.
[41] R. Haque, A. R. b. S. Senathirajah, M. I. Khalil, S. Z. Qazi, and S. Ahmed, "A structural path analysis Bangladeshi smes'sustainability through social media marketing," *Sustainability*, vol. 16, no. 13, p. 5433, 2024. https://doi.org/10.3390/su16135433
[42] H. Zameer, Y. Wang, H. Yasmeen, and S. Mubarak, "Green innovation as a mediator in the impact of business analytics and environmental orientation on green competitive advantage," *Management Decision*, vol. 60, no. 2, pp. 488-507, 2022. https://doi.org/10.1108/MD-02-2021-0355
[43] S. Singh *et al.*, *Bibliometric review on healthcare sustainability* (Handbook of research on safe disposal methods of municipal solid wastes for a sustainable environment). IGI Global. https://doi.org/10.4018/978-1-6684-8117-2.ch009, 2023.
[44] O. A. Almuhatresh, A. R. bin S Senathirajah, and R. Haque, "Factors influencing online purchase intention of smartphones in Bahrain," *International Journal of Operations and Quantitative Management*, vol. 28, no. 2, pp. 617-629, 2022. https://doi.org/10.46970/2022.28.2.12
[45] J. Kaur and K. N. Singh, "An exploratory study on innovative competency mapping and its relevance for talent management," *Journal of Information and Optimization Sciences*, vol. 43, no. 7, pp. 1589-1599, 2022. https://doi.org/10.1080/02522667.2022.2138218
[46] H. Fatorachian and H. Kazemi, "Impact of Industry 4.0 on supply chain performance," *Production Planning & Control*, vol. 32, no. 1, pp. 63-81, 2021. https://doi.org/10.1080/09537287.2020.1712487
[47] J. Kaur, A. Dutt, P. Bhalla, V. K. Poddar, and V. Kumra, *Recharging creativity: Embracing digital detox for entrepreneurial excellence. In Business Drivers in Promoting Digital Detoxification*. IGI Global. https://doi.org/10.4018/979-8-3693-1107-3.ch015, 2024.
[48] M. Halme, J. Rintamäki, J. S. Knudsen, L. Lankoski, and M. Kuisma, "When is there a sustainability case for CSR? Pathways to environmental and social performance improvements," *Business & Society*, vol. 59, no. 6, pp. 1181-1227, 2020. https://doi.org/10.1177/0007650318755648

[49] P. X. Lee *et al.*, "Factors influencing job hopping behaviour amongst finance professionals: Towards improving employment policy," *International Journal of Operations and Quantitative Management*, vol. 29, no. 2, pp. 360-377, 2023. https://doi.org/10.46970/2023.29.2.17

[50] C. Chisala, A. Senathirajah, R. Haque, and A. Pang, "A comparative assessment of cluster and non-cluster based SMEs in Zambia," *Science International Journal*, vol. 30, no. 5, pp. 763-766, 2018.

[51] L. K. Leong, L. Manickam, R. Haque, K. Jumbulingam, and N. Noordin, "Embracing digital transformation for sustainable business in the construction industry," *Pakistan Journal of Life and Social Sciences*, vol. 22, no. 2, pp. 1621-1640, 2024. https://doi.org/10.57239/PJLSS-2024-22.2.00113

[52] L. Wang, R. Haque, N. Hakimi, and C. Guanyu, "Examining digital talent acquisition and recruitment strategies to enhance economic sustainable development goals (SDGS) Of SME'S in China's Internet industry," *Journal of Lifestyle and SDGs Review*, vol. 4, no. 3, pp. e02306-e02306, 2024. https://doi.org/10.47172/2965-730X.SDGsReview.v4.n03.pe02306

[53] P. D. Barman and R. Haque, "Role of students in economic growth towards intention of social entrepreneurship development in Bangladesh," *MAHSA International Journal of Business and Social Sciences*, vol. 2, no. 2, pp. 136–148, 2022.

[54] R. Aziz *et al.*, "A study of the relationship between leadership styles and project success," *Res Militaris, European Journal of Military Studies*, vol. 12, no. 4, pp. 1900-1907, 2022.

[55] M. C. S. Chinn, R. Bhardwaj, A. Lary, A. R. bin S Senathirajah, R. Haque, and A. Nazneen, "Keeping talent close: A deep dive into employee retention in the Malaysian financial industry," *Journal of Ecohumanism*, vol. 4, no. 2, pp. 299–319, 2025. https://doi.org/10.62754/joe.v4i2.5994

[56] Q. Bin, A. b. S. Senathirajah, and R. Haque, "Predictors of patients' satisfaction based on service quality dimensions," *Journal of Pharmaceutical Negative Results*, vol. 13, no. 9, pp. 10336-10343, 2022. https://doi.org/10.47750/pnr.2022.13.S09.1211

[57] P. Haibin, A. Senathirajah, G. Connie, and R. Haque, "Investigating pull factors in international tourist travel motivation: An empirical analysis on the Malaysian tourism industry," *Baltic Journal of Law & Politics*, vol. 15, no. 2, pp. 564-576, 2022. https://doi.org/10.2478/bjlp-2022-001034

[58] R. Haque, T. A. Siddiqui, L. H. San, and F. M. B. O. Din, "Data visualization: A study of tools and challenges," *MAHSA International Journal of Business and Social Sciences*, vol. 2, no. 1, pp. 71-78, 2022.

[59] P. Malnaad, A. R. bin S Senathirajah, G. Connie, Z. Osman, and R. Haque, "An examination on e-banking service quality and its significance on e-satisfaction and e-loyalty: An Asian study," *Journal of Positive School Psychology*, vol. 6, no. 6, pp. 8169-8185, 2022.

[60] M. Josephine *et al.*, "Tax evasion – black economy of india: A study on the factors influencing tax evasion," *Science International Journal*, vol. 30, no. 3, pp. 387-392, 2018.

[61] P. Bhalla, J. Kaur, and S. Zafar, *Journey from FOMO to JOMO by digital detoxification. In Business drivers in promoting digital detoxification*. IGI Global. https://doi.org/10.4018/979-8-3693-1107-3.ch012, 2024.

[62] A. McMahon, "Global equitable access to vaccines, medicines and diagnostics for COVID-19: The role of patents as private governance," *Journal of Medical Ethics*, vol. 47, no. 3, pp. 142-148, 2021. https://doi.org/10.1136/medethics-2020-106795

[63] A. Nazneen, P. Bhalla, S. Qazi, and J. Kaur, "Integrated web of youth happiness measures," *International Journal of Data & Network Science*, vol. 8, no. 2, pp. 1085-1098, 2024.

[64] N. S. Mosavi and M. F. Santos, "How prescriptive analytics influences decision making in precision medicine," *Procedia Computer Science*, vol. 177, pp. 528–533, 2021. https://doi.org/10.1016/j.procs.2020.10.073

[65] S. Goyal, J. Kaur, S. Qazi, and P. Bhalla, "Moderating effect of perceived organizational support in the relationship between thriving at work and work performance," *International Journal of eBusiness and eGovernment Studies*, vol. 15, no. 2, pp. 187-211, 2023. https://doi.org/10.34109/ijebeg.2023150210

[66] T. Behl *et al.*, "The road to precision medicine: Eliminating the "One size fits all" approach in Alzheimer's disease," *Biomedicine & Pharmacotherapy*, vol. 153, p. 113337, 2022. https://doi.org/10.1016/j.biopha.2022.113337

[67] L. J. Basile, N. Carbonara, R. Pellegrino, and U. Panniello, "Business intelligence in the healthcare industry: The utilization of a data-driven approach to support clinical decision making," *Technovation*, vol. 120, p. 102482, 2023. https://doi.org/10.1016/j.technovation.2022.102482

[68] R. Dahiya, S. Le, J. K. Ring, and K. Watson, "Big data analytics and competitive advantage: The strategic role of firm-specific knowledge," *Journal of Strategy and Management*, vol. 15, no. 2, pp. 175-193, 2022. https://doi.org/10.1108/JSMA-08-2020-0203

[69] M. I. Khalil and R. Haque, "Impact of dynamic leadership style on SME's," *MAHSA International Journal of Business and Social Sciences*, vol. 2, no. 2, pp. 118-135, 2022.

[70] S. W. Soon, R. Bhardwaj, S. Z. Qazi, A. R. B. S. Senathirajah, R. Haque, and H. N. Krishnasamy, "Factors Influencing Talent Retention in Malaysia's Semiconductor Industry," *Journal of Ecohumanism*, vol. 4, no. 3, pp. 1-33, 2025. https://doi.org/10.62754/joe.v4i3.6191

[71] O. M. Araz, T. M. Choi, D. L. Olson, and F. S. Salman, "Role of analytics for operational risk management in the era of big data," *Decision Sciences*, vol. 51, no. 6, pp. 1320-1346, 2020. https://doi.org/10.1111/deci.12451

[72] J. Kaur and G. Madaan, *Blockchain technology: Application in electronic health-care systems. In S. S. K. Iyer & S. K. Bansal (Eds.), Blockchain for Business: Promise, Practice, and Applications*. Cham: Springer, 2023.

[73] J. O. H. Liaw, N. Ibrahim, I. Singh, A. Tajudin, A. Isa, and R. Haque, "Integration model of human dimensions, military minds and patriostism," *International Journal of Religion*, vol. 5, no. 11, pp. 2581-2597, 2024. https://doi.org/10.61707/jakg979

[74] E. Tucker, "Strategic workforce planning: From closing skills gaps to optimizing talent," *Strategic HR Review*, vol. 21, no. 1, pp. 14-19, 2022.

[75] J. Kaur, "Women entrepreneurship: Challenges and issues," *International Journal of Management, Technology and Engineering*, vol. 9, no. 4, pp. 491-506, 2019.

[76] N. Aggrawal and A. Pandey, *Enhancing people management through strategic analytics in Indian corporate landscape* (Using Strategy Analytics for Business Value Creation and Competitive Advantage). IGI Global. https://doi.org/10.4018/979-8-3693-2823-1, 2024, pp. 116-155.

[77] U. Awan, S. Shamim, Z. Khan, N. U. Zia, S. M. Shariq, and M. N. Khan, "Big data analytics capability and decision-making: The role of data-driven insight on circular economy performance," *Technological Forecasting and Social Change*, vol. 168, p. 120766, 2021. https://doi.org/10.1016/j.techfore.2021.120766

[78] H. E. Adama, O. A. Popoola, C. D. Okeke, and A. E. Akinoso, "Theoretical frameworks supporting IT and business strategy alignment for sustained competitive advantage," *International Journal of Management & Entrepreneurship Research*, vol. 6, no. 4, pp. 1273-1287, 2024. https://doi.org/10.51594/ijmer.v6i4.1058

[79] M. Kimura, "Customer segment transition through the customer loyalty program," *Asia Pacific Journal of Marketing and Logistics*, vol. 34, no. 3, pp. 611-626, 2022. https://doi.org/10.1108/APJML-09-2020-0630

[80] K. Umesh, A. Senathirajah, G. Connie, and R. Haque, "Examining factors influencing blockchain technology adoption in air pollution monitoring," *International Journal of Intelligent Systems and Applications in Engineering*, vol. 11, pp. 334-344, 2023. https://doi.org/10.18280/ijisae.1104s.45

[81] A. Senathirajah and R. Haque, "A phenomenological study exploring consumers' perception of e-service quality: A case study on online shoppers," *European Journal of Military Studies*, vol. 12, no. 2, pp. 1250-1262, 2022.